Search

Displaying results 2031 - 2040 of 4646 in total
  1. Drug

    Acetrizoic acid

    go.drugbank.com/drugs/DB09347
    ApprovedWithdrawn

    [A32135] It was first synthesized by Wallingford in 1953[A32136] and it was filled in the FDA by the Johnson & Johnson subsidiary, Cilag Chemie AG, on February 8th, 1978.

  2. Drug

    Arbutin

    go.drugbank.com/drugs/DB11217
    Approved

    Arbutin was shown to be less cytotoxic to melanocytes in culture compared to [DB09526] [A32942]. … Arbutin is available in both natural and synthetic forms; it can be synthesized from acetobromglucose and [DB09526] [F43].

    Mixtures: AHC Vital Complex C-15 Ampoule, Dr G Whitening REFORMER by EGF
  3. Drug

    Tipiracil

    go.drugbank.com/drugs/DB09343
    ApprovedInvestigational

    Tipiracil is a thymidine phosphorylase inhibitor. It is used in combination with trifluridine, in a ratio of 1:0.5, to form TAS-102. The main function of Tipiracil in TAS-102 is to increase trifluridine bioavailability by inhibiting its ...

    Synonyms: 5-chloro-6-(2-iminopyrrolidin-1-yl)methyl-2,4(1H,3H)-pyrimidinedione, 5-chloro-6-[(2-iminopyrrolidin-1-yl)methyl]-1H-pyrimidine-2,4-dioneMixtures: LONSURF FILM-COATED TABLET 15 MG/6.14 MG, LONSURF FILM-COATED TABLET 15 MG/6.14 MG
  4. Drug

    Delorazepam

    go.drugbank.com/drugs/DB01511
    IllicitInvestigational

    In addition to be long acting, delorazepam is relatively potent, with 1 mg of delorazepam being the equivalent of 10 mg diazepam. It has been approved for marketing in Italy.

    International brands: Delorazepam EGProducts: DELORAZEPAM EG
  5. Drug

    Talimogene laherparepvec

    go.drugbank.com/drugs/DB13896
    ApprovedInvestigational

    It is a genetically administered herpes simplex virus 1 (HSV-1) that expresses human cytokine granulocyte-macrophage colony stimulating factor (GM-CSF) with antitumor and immune-stimulating activities.

  6. Drug

    Lithium chloride

    go.drugbank.com/drugs/DB16607
    Investigational

    Products: Lithiumchlorid LiDCO 0,15 mmol/ml Injektionslösung
  7. Drug

    Dinalbuphine sebacate

    go.drugbank.com/drugs/DB15341
    Investigational

    Dinalbuphine sebacate is under investigation in clinical trial NCT02468128 (A Study of Intramuscular Sebacoyl Dinalbuphine Ester for Post-Hemorrhoidectomy Pain Management).

    Products: NALDEBAIN® EXTENDED RELEASE INJECTION 75MG/ML
  8. Drug

    Atacicept

    go.drugbank.com/drugs/DB06399
    ApprovedInvestigational

    [L63797] The US FDA granted accelerated approval to atacicept-vymj on July 7, 2026, to reduce proteinuria in adults with primary IgA nephropathy at risk for disease progression. … Atacicept is a recombinant fusion glycoprotein that joins the ligand-binding portion of the human TACI receptor to a modified IgG1 Fc domain, allowing it to bind and neutralize two cytokines: B cell activating

    Synonyms: TACI-IG
  9. Drug

    Nuvaxovid

    go.drugbank.com/drugs/DB15810
    ApprovedInvestigational

    Nuvaxovid (NVX-CoV2373) contains a recombinant mutant S protein that is codon-optimized for baculovirus-mediated expression in Sf9 cells derived from _Spodoptera frugiperda_ together with a Matrix-M adjuvant

  10. Drug

    Sugemalimab

    go.drugbank.com/drugs/DB16641
    ApprovedInvestigational

    Sugemalimab is a fully human, full-length anti-programmed death-ligand 1 (PD-L1) monoclonal antibody (of the IgG4 isotype) discovered by CStone Pharmaceuticals. … [L53333] The drug achieves this through a dual mechanism of action involving binding to the programmed cell death-ligand 1 (PD-L1) and also through inducing antibody-dependent cellular phagocytosis.

    Categories: PD-1/PD-L1 (Programmed cell death protein 1/death ligand 1) inhibitors